Friday, May 19, 2017 9:04:37 PM
?$C.MARI $1.75... Marijuana growing facility.. Very low float "Discount price "Check it out... 
After Germany announced plans to legalize medical cannabis at the federal level, there was significant increase in the number of companies focused on this market.
The expansion makes complete sense and we expect to see the number of firms levered to the German medical cannabis market continue to increase.
Germany has the largest population in the European Union and registered patients will have their medical cannabis covered by insurance. These factors combined with Germany being a cannabis friendly country (more than 22% of adults have tried cannabis) lead us to expect a high patient adoption rate.
Although Germany began to allow access to medical cannabis in 2005, domestic production does not yet exist and the country relies solely on imported products. This has created a multi-billion-dollar opportunity for international cannabis producers and has made Germany a very attractive market for cannabis companies.
Despite these positive characteristics, there are significant barriers to enter the German medical cannabis market. The country imposes very high standards for imports from a quality and consistency standpoint and a complex regulatory environment for importing and distributing cannabis.
These high barriers to entry have not deterred potential producers and the number of firms (especially Canadian producers) trying to enter the market continues to increase. The reason why Canada is positioned to capitalize on this market is because they already operate under Health Canada’s stringent rules and regulations.
Cronos Products are Sold out of 200+ Pharmacies
Since October, Cronos Group has been distributing cannabis to Germany via its wholly owned subsidiary, Peace Naturals Project Inc.
In an interview with Benzinga, Cronos Group CEO Mike Gorenstein said, “We see Germany and other places in Europe as extremely attractive [markets] because cannabis is treated as a medicine. Like any other medicine, you receive a prescription for it from your doctor, and insurance is mandated to cover it.”
At the time of this interview, Gorenstein said that roughly 200 pharmacies in the European country currently sell their products. This is a very attractive aspect of the company and we expect to see this number increase as the market continues to mature and grow.
A Canadian Cannabis Producer to Watch
In late 2016, leading Canadian medical cannabis producer Canopy Growth (TWMJF) (CGC.TO) acquired MedCann GmbH Pharma and Nutraceuticals, a German-based pharmaceutical distributor that has placed Tweed-branded cannabis strains in German pharmacies. MedCann is federally licensed by the German Health Ministry to import, manufacture and distribute medical cannabis products.
Canopy's various production sites have a track record of producing consistent strains that yield reliable cannabinoid profiles harvest after harvest. This was an important aspect of the due diligence process as such consistency is a federal requirement for cannabis exports entering Germany.
Maricann Goes Public and Offers Leverage to Germany
Last week, Maricann Group (MARI.CN: CSE) secured $42.5 million in non-dilutive financing to further expand production in Germany. The capital came from a Vancouver-based firm that provides non-equity financing solutions for cannabis producers. In return, Maricann will provide the company the right to purchase 20% of production at an all-in cost plus 10% from this expansion in Germany.
Maricann will use the capital for its 150,000-sq. ft. expansion at its Ebersbach Facility and an additional 250,000 sq. ft. in a two-tiered cultivation plan. The capital will also be used for an outdoor hemp farm for cannabis that is high in cannabidiol (CBD).
The Ebersbach facility was built 20 years ago and is comprised of multiple individual clean rooms. The facility will not require too much capital to revamp and the company said the infrastructure needed to grow cannabis in an indoor secured environment is already in place.
In late April, Maricann commenced trading on the Canadian Securities Exchange. A few days later the company announced an Advisory Board for its German subsidiary. This is a company to watch. Maricann is a vertically integrated Canadian producer and distributor of medical cannabis. Since its inception, the company has been servicing a patient base of 8,000+ total registered patients.
https://technical420.com/cannabis-article/3-ways-capitalize-german-cannabis-market
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.mari&postid=26218004#jswfOm59xiIV5ZYq.99
After Germany announced plans to legalize medical cannabis at the federal level, there was significant increase in the number of companies focused on this market.
The expansion makes complete sense and we expect to see the number of firms levered to the German medical cannabis market continue to increase.
Germany has the largest population in the European Union and registered patients will have their medical cannabis covered by insurance. These factors combined with Germany being a cannabis friendly country (more than 22% of adults have tried cannabis) lead us to expect a high patient adoption rate.
Although Germany began to allow access to medical cannabis in 2005, domestic production does not yet exist and the country relies solely on imported products. This has created a multi-billion-dollar opportunity for international cannabis producers and has made Germany a very attractive market for cannabis companies.
Despite these positive characteristics, there are significant barriers to enter the German medical cannabis market. The country imposes very high standards for imports from a quality and consistency standpoint and a complex regulatory environment for importing and distributing cannabis.
These high barriers to entry have not deterred potential producers and the number of firms (especially Canadian producers) trying to enter the market continues to increase. The reason why Canada is positioned to capitalize on this market is because they already operate under Health Canada’s stringent rules and regulations.
Cronos Products are Sold out of 200+ Pharmacies
Since October, Cronos Group has been distributing cannabis to Germany via its wholly owned subsidiary, Peace Naturals Project Inc.
In an interview with Benzinga, Cronos Group CEO Mike Gorenstein said, “We see Germany and other places in Europe as extremely attractive [markets] because cannabis is treated as a medicine. Like any other medicine, you receive a prescription for it from your doctor, and insurance is mandated to cover it.”
At the time of this interview, Gorenstein said that roughly 200 pharmacies in the European country currently sell their products. This is a very attractive aspect of the company and we expect to see this number increase as the market continues to mature and grow.
A Canadian Cannabis Producer to Watch
In late 2016, leading Canadian medical cannabis producer Canopy Growth (TWMJF) (CGC.TO) acquired MedCann GmbH Pharma and Nutraceuticals, a German-based pharmaceutical distributor that has placed Tweed-branded cannabis strains in German pharmacies. MedCann is federally licensed by the German Health Ministry to import, manufacture and distribute medical cannabis products.
Canopy's various production sites have a track record of producing consistent strains that yield reliable cannabinoid profiles harvest after harvest. This was an important aspect of the due diligence process as such consistency is a federal requirement for cannabis exports entering Germany.
Maricann Goes Public and Offers Leverage to Germany
Last week, Maricann Group (MARI.CN: CSE) secured $42.5 million in non-dilutive financing to further expand production in Germany. The capital came from a Vancouver-based firm that provides non-equity financing solutions for cannabis producers. In return, Maricann will provide the company the right to purchase 20% of production at an all-in cost plus 10% from this expansion in Germany.
Maricann will use the capital for its 150,000-sq. ft. expansion at its Ebersbach Facility and an additional 250,000 sq. ft. in a two-tiered cultivation plan. The capital will also be used for an outdoor hemp farm for cannabis that is high in cannabidiol (CBD).
The Ebersbach facility was built 20 years ago and is comprised of multiple individual clean rooms. The facility will not require too much capital to revamp and the company said the infrastructure needed to grow cannabis in an indoor secured environment is already in place.
In late April, Maricann commenced trading on the Canadian Securities Exchange. A few days later the company announced an Advisory Board for its German subsidiary. This is a company to watch. Maricann is a vertically integrated Canadian producer and distributor of medical cannabis. Since its inception, the company has been servicing a patient base of 8,000+ total registered patients.
https://technical420.com/cannabis-article/3-ways-capitalize-german-cannabis-market
Read more at http://www.stockhouse.com/companies/bullboard?symbol=c.mari&postid=26218004#jswfOm59xiIV5ZYq.99
"TAKE THOSE MOTHERS DOWN..!!!!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
